News headlines about PharMerica (NYSE:PMC) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PharMerica earned a news impact score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0058846195224 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised PharMerica from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Wednesday, September 27th. ValuEngine raised PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $30.50.

PharMerica (PMC) opened at $29.25 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.79 and a current ratio of 2.58. The firm has a market capitalization of $910.27, a P/E ratio of 15.15, a P/E/G ratio of 1.27 and a beta of 0.82. PharMerica has a 1-year low of $22.00 and a 1-year high of $29.50.

PharMerica (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The business had revenue of $595.10 million for the quarter, compared to analyst estimates of $596.80 million. PharMerica had a return on equity of 10.94% and a net margin of 0.83%. analysts anticipate that PharMerica will post 1.92 earnings per share for the current fiscal year.

In related news, CEO Gregory S. Weishar sold 521,089 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $29.25, for a total transaction of $15,241,853.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 534,089 shares of company stock worth $15,243,073 over the last three months. 5.04% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact PharMerica (PMC) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-pharmerica-pmc-share-price.html.

PharMerica Company Profile

Insider Buying and Selling by Quarter for PharMerica (NYSE:PMC)

Receive News & Stock Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related stocks with our FREE daily email newsletter.